Upside – $LPCN +40% (Health Canada approves TLANDO for testosterone replacement therapy) – $APUS +9.4% (extends a high-volume rally tied to the BlockAssure agreement to build and operate the AssureChain insurance network) – $PENG +4.3% (Q4 beat and FY27 sales and EPS outlook topped prior guidance and Street expectations on accelerating AI-infrastructure demand) – CNQ …
Read in context ›Apimeds Pharmaceuticals US, Inc. Stock (APUS)
Track Apimeds Pharmaceuticals US, Inc. stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
APUS
Apimeds Pharmaceuticals US, Inc.
general
$7.99
▼ -11.27 (-61.25%) past year
Market Cap
$6.93M
P/E Ratio
—
1Y Return
-61.25%
EPS (TTM)
-$36.71
Read the latest TheStreet Pro articles mentioning Apimeds Pharmaceuticals US, Inc., including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning APUS yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning